Literature DB >> 11224491

The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels.

M Margaglione1, A Bossone, G Cappucci, D Colaizzo, E Grandone, G Di Minno.   

Abstract

BACKGROUND AND OBJECTIVES: C-reactive protein (C-RP) levels correlate with fibrinogen values and are predictive of coronary artery disease. Interleukin-6 (IL-6) strongly regulates the production of C-RP. A polymorphism (C/G-174) within the IL-6 gene has been shown to affect IL-6 gene expression and plasma concentrations. DESIGN AND METHODS: In 598 asymptomatic employees of a hospital in Southern Italy, we investigated the association between IL-6 C/G-174 gene variants and plasma fibrinogen levels.
RESULTS: Subjects with IL-6 plasma levels >2.0 pg/mL had a higher body mass index (BMI) (24.5+/-1.2) than subjects with IL-6 levels below this cut-off value (23.7+/-1.2; p =0.005). No association was found with sex, cigarette smoking, or alcohol consumption (p always>0.05). When the whole sample was analyzed according to the IL-6 C/G-174 polymorphism, there was no difference with respect to age, sex, alcohol consumption, cigarette smoking, total cholesterol, triglycerides, and body mass index. Median plasma fibrinogen levels, as well as carriers of plasma levels of IL-6 >2.0 pg/mL and C-RP >0.33 mg/L, were similar among subjects with different IL-6 genotypes. Similarly, no difference was observed when only carriers of plasma levels of IL-6 >2.0 pg/mL were analyzed, whereas in those with C-RP >0.33 mg/L IL-6 GG carriers had significantly lower plasma fibrinogen levels. INTERPRETATION AND
CONCLUSIONS: The investigation of the IL-6 C/G-174 polymorphism does not seem to be a useful tool for predicting raised plasma fibrinogen levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224491

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

1.  A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.

Authors:  Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-22       Impact factor: 4.254

2.  Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

Authors:  Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

3.  Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans.

Authors:  Heiner K Berthold; Matthias Laudes; Wilhelm Krone; Ioanna Gouni-Berthold
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

4.  Linkage study of fibrinogen levels: the Strong Heart Family Study.

Authors:  Lyle G Best; Kari E North; Xia Li; Vittorio Palmieri; Jason G Umans; Jean MacCluer; Sandy Laston; Karin Haack; Harald Goring; Vincent P Diego; Laura Almasy; Elisa T Lee; Russell P Tracy; Shelley Cole
Journal:  BMC Med Genet       Date:  2008-08-12       Impact factor: 2.103

5.  STOP Pain Project-Opioid Response in Pediatric Cancer Patients and Gene Polymorphisms of Cytokine Pathways.

Authors:  Giada Crescioli; Niccolò Lombardi; Laura Vagnoli; Alessandra Bettiol; Laura Giunti; Valentina Cetica; Maria Luisa Coniglio; Aldesia Provenzano; Sabrina Giglio; Roberto Bonaiuti; Alessandro Mugelli; Maurizio Aricò; Andrea Messeri; Alfredo Vannacci; Valentina Maggini
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.